Nami Surgical has announced the launch of its latest fundraising campaign, aiming to raise $10 million by December 2025 to accelerate global expansion and bring its world-first technology into operating rooms worldwide.

The campaign follows a transformative 18 months for the company, which has seen Nami close its first $4.3 million investment round, secure world-class expertise for its team and board, and achieve major technical milestones in the development of its patented ultrasonic technology.

Pioneering Technology in Robotic-Assisted Surgery

At the heart of Nami Surgical’s innovation is the miniaturised ultrasonic scalpel — the first of its kind designed to bridge the integration gap in robotic-assisted surgery.

Conventional ultrasonic scalpels are essential tools for laparoscopic minimally invasive procedures, enabling surgeons to dissect and cauterise soft tissue while sealing blood vessels. However, their size has long prevented integration with robotic surgical systems, limiting adoption in a fast-growing market.

Nami Surgical has solved this challenge. Its scalpel integrates seamlessly with wristed robotic joints, passes through standard 8mm surgical ports, and articulates fully within the body. Combined with a modular, smart ultrasonic driving system that controls energy delivery with precision, Nami has demonstrated device performance on par with market-leading solutions — while being more than 90% smaller than existing technologies.

The opportunity for innovation is vast. Over 2 million robotic-assisted procedures were performed in 2024, and adoption is accelerating rapidly.

The NHS has committed to increasing robot-assisted keyhole operations from 70,000 to 500,000 annually by 2035, with projections that nine out of ten procedures will be robot-assisted. Globally, the surgical robotics market was valued at more than USD 8 billion in 2024 and is forecast to exceed USD 30 billion by 2035, with over 50% of recurring revenue generated from surgical instruments and accessories.

For patients, robotic-assisted surgery promises less pain, faster recovery, and fewer complications. For hospitals, it brings greater precision, shorter operating times, and the ability to take on more complex procedures.

Proceeds from this new fundraising round will be used to:

  • Launch a market-ready platform by advancing our soft-tissue robotic-assisted surgical technologies and cementing our lead in miniaturised ultrasonic innovation.
  • Scale R&D capacity to enable high-volume prototyping and rapid testing, shortening development cycles.
  • Unlock new high-value applications in bone-tissue surgery — a market where precision, control, and tissue selectivity are critical.
  • Expand our leadership team to accelerate global commercialisation, strategic partnerships, and long-term stakeholder value.

The raise, which opened in July 2025, has already secured continued backing from existing investors.

Dr Nico Fenu, Co-founder and CEO, described the campaign as a pivotal step for the company:

“We are now fully focused on our Series A round—an important and defining moment for our team. This funding will unlock an exciting phase of commercial partnerships and shape what’s possible for our ultrasonic platform across multiple verticals. It will allow us to expand our capabilities, strengthen our already exceptional team, and move decisively toward our goal of bringing Nami’s core technology into operating rooms globally.”

Nami Surgical is seeking investment partners with proven expertise in robotic-assisted surgery and medical device hardware to help scale its innovation globally and capture a significant share of this fast-growing market.

Investors interested in exploring opportunities to partner are invited to contact:

Dr Nico Fenu, Co-founder & CEO — nico.fenu@namisurgical.com